Unfortunately highly active antiretroviral therapy (HAART) has been recognized to be increasingly associated with the emergence of morphological and metabolic disorders, mainly dyslipidemia, insulin resistance and fat redistribution syndromes, the so-called lipodystrophy syndrome [1].